National Bank of Canada FI Buys 178,383 Shares of Cencora, Inc. $COR

National Bank of Canada FI increased its stake in Cencora, Inc. (NYSE:COR) by 228.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 256,449 shares of the company’s stock after purchasing an additional 178,383 shares during the period. National Bank of Canada FI owned approximately 0.13% of Cencora worth $76,894,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of COR. Norges Bank bought a new position in shares of Cencora during the second quarter worth about $695,215,000. Artisan Partners Limited Partnership acquired a new position in Cencora during the 2nd quarter worth approximately $411,888,000. Vanguard Group Inc. grew its stake in shares of Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after acquiring an additional 1,125,661 shares in the last quarter. Viking Global Investors LP raised its holdings in shares of Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its position in shares of Cencora by 4,459.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock worth $277,321,000 after purchasing an additional 975,362 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. UBS Group raised their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Wells Fargo & Company upped their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Robert W. Baird raised their price target on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $373.50.

Insider Activity

In related news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer owned 65,746 shares of the company’s stock, valued at $24,105,113.44. This trade represents a 7.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 46,640 shares of company stock valued at $14,099,338 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

Shares of NYSE COR opened at $345.86 on Monday. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The business’s 50 day moving average price is $343.29 and its two-hundred day moving average price is $311.48. The company has a market cap of $67.09 billion, a PE ratio of 43.50, a price-to-earnings-growth ratio of 1.64 and a beta of 0.63. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the company posted $3.34 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is currently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.